CAPTRUST Financial Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,597	Closed	-$36K	–	4210
2022 Q2	$36K	Buy	2,597 +384	+17%	+$5.91K	﹤0.01%	3004
2022 Q1	$43K	Sell	2,213 -449	-17%	-$6.81K	﹤0.01%	2907
2021 Q4	$43K	Buy	2,662 +788	+42%	+$13.1K	﹤0.01%	2777
2021 Q3	$52K	Hold	1,874	–	–	﹤0.01%	2552
2021 Q2	$56K	Sell	1,874 -500	-21%	-$14.4K	﹤0.01%	2446
2021 Q1	$66K	Buy	2,374 +632	+36%	+$17.5K	﹤0.01%	2246
2020 Q4	$49K	Hold	1,742	–	–	﹤0.01%	1839
2020 Q3	$44K	Hold	1,742	–	–	﹤0.01%	1681
2020 Q2	$44K	Buy	+1,742	New	+$34.4K	﹤0.01%	1667
2019 Q4	–	Sell	-200	Closed	-$3K	–	1868
2019 Q3	$3K	Hold	200	–	–	﹤0.01%	1760
2019 Q2	$3K	Hold	200	–	–	﹤0.01%	1762
2019 Q1	$3K	Hold	200	–	–	﹤0.01%	1651
2018 Q4	$4K	Hold	200	–	–	﹤0.01%	1401
2018 Q3	$5K	Hold	200	–	–	﹤0.01%	1366
2018 Q2	$5K	Hold	200	–	–	﹤0.01%	1332
2018 Q1	$6K	Hold	200	–	–	﹤0.01%	1143
2017 Q4	$7K	Hold	200	–	–	﹤0.01%	1084
2017 Q3	$6K	Buy	+200	New	+$4.85K	﹤0.01%	478

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CAPTRUST Financial Advisors's RVNC Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2022, closing a stake of 2,597 shares — an estimated $36K sold.

CAPTRUST Financial Advisors first reported a position in RVNC in Q3 2017 and held it in 18 quarters. The position peaked at $66K in Q1 2021. 182 funds tracked by Wall St. Rank hold RVNC as of Q3 2022.

CAPTRUST Financial Advisors reported no remaining Revance Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 2,597 Revance Therapeutics, Inc. shares in Q3 2022, an estimated $36K.
CAPTRUST Financial Advisors first reported a position in Revance Therapeutics, Inc. in Q3 2017 and held it in 18 quarters.
CAPTRUST Financial Advisors's Revance Therapeutics, Inc. position peaked at $66K in Q1 2021.
182 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.